<DOC>
	<DOCNO>NCT00003891</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness lurtotecan liposome treat patient advance solid tumor .</brief_summary>
	<brief_title>Lurtotecan Liposome Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) future dose lurtotecan liposome patient advance solid tumor . II . Assess toxicity pharmacokinetics treatment regimen patient population . III . Assess response regimen patient measurable disease . OUTLINE : This dose escalation , multicenter study . Patients receive lurtotecan liposome ( NX211 ) IV 30 minute day 1 , 2 , 3 . Courses repeat every 3 week . Treatment continue 6 course absence unacceptable toxicity disease progression . The dose NX211 escalate cohort 3-6 patient maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . Patients follow 4 week every 3 month 1 year . PROJECTED ACCRUAL : A total 20-25 patient accrue study within 12-15 month .</detailed_description>
	<mesh_term>Lurtotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced solid tumor unresponsive exist therapy curative therapy exist Evidence disease tumor marker elevation No untreated CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great upper limit normal ( ULN ) AST ALT great 2.5 time ULN ( great 5 time ULN liver metastasis ) Renal : Creatinine great upper limit normal Cardiovascular : Not specify Pulmonary : Not specify Other : No prior malignancy within past 5 year except curatively treat basal squamous cell skin cancer carcinoma situ cervix Not pregnant nursing Fertile patient must use effective contraception No active uncontrolled infection No serious illness medical condition No known hypersensitivity systemic liposomal formulation drug chemically relate study drug PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No great 3 prior chemotherapy regimen ( adjuvant metastatic ) At least 3 week since prior adjuvant metastatic chemotherapy ( 6 week nitrosoureas mitomycin 4 week carboplatin experimental anti cancer drug ) recover At least 1 year since prior high dose chemotherapy bone marrow stem cell support No concurrent chemotherapy Endocrine therapy : Prior hormonal therapy allow No concurrent hormonal therapy Radiotherapy : No prior radiotherapy great 25 % bone marrow At least 4 week since prior radiotherapy , except low dose myelosupressive radiotherapy , recover Concurrent palliative radiotherapy allow Surgery : Not specify Other : At least 4 week since prior experimental drug anticancer therapy No concurrent investigational anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>